AdvanCell
Clinical‑stage radiopharmaceutical company developing targeted alpha therapies using lead‑212 (²¹²Pb) for cancers with poor existing standards of care.
A venture-stage stake in an established Australian programme.
AdvanCell is a clinical‑stage Australian radiopharmaceutical company developing targeted alpha therapies for cancers with poor existing standards of care. Its lead asset, ²¹²Pb‑ADVC001, uses lead‑212 — a short‑range, high‑energy alpha emitter — bound to PSMA‑targeting molecules, delivering a precise dose of radiation to prostate cancer cells while sparing surrounding tissue.
The Phase 1b TheraPb readout at ESMO in October 2025 showed an 80% PSA50 response at doses ≥160 MBq, 100% objective response in RECIST‑measurable lesions, two complete responses, and no dose‑limiting toxicities. The Phase 2 expansion initiated in December 2025 is enrolling across mHSPC and mCRPC indications, with topline data planned for late 2026.
Proto Axiom holds a venture‑stage investment in AdvanCell alongside Sanofi, Brandon Capital, Time Bio and others. The company is independently led by CEO Philina Lee from a Boston US HQ, with Australian operations led by Managing Director Andrew Adamovich.
- Invested
- 2024
- Origin
- Sydney, Australia
- Sector
- Therapeutics
- Modality
- Radiopharmaceuticals · Targeted alpha therapy
Independently led; see the company website for the full team.
Where the programme is now, and what comes next.
- Now
- Phase 2 ²¹²Pb‑ADVC001 expansion across mHSPC and mCRPC indications. Lead‑212 / Thorium‑228 manufacturing scale‑up at Brisbane facility.